Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01602380 · ClinicalTrials.gov registry record · Phase 3
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
A Phase 3 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 3
- Development phase
- 462
- Enrollment target
NCT01602380 is a Phase 3 study that has completed, run by AstraZeneca. The registered enrollment target is 462 participants.
The verdict
NCT01602380, a Phase 3 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 462 participants
- Enrollment target
Study Summary
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.
Interventions
- DRUG faslodex 500mg
- DRUG arimidex 1mg
- DRUG faslodex dummy
- DRUG arimidex dummy
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 462 participants |
| Start Date | 2012-10-17 |
| Est. Completion | 2026-01-16 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01602380
The ClinicalTrials.gov registry entry for NCT01602380 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 462 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which faslodex 500mg is the first listed.
NCT01602380 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01602380 about?
NCT01602380 is a clinical study titled "A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.". The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal treatment.
What is the current status of trial NCT01602380?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 462 participants. The study started on 2012-10-17. Estimated completion is 2026-01-16.
What interventions are being tested in trial NCT01602380?
The interventions under investigation include: faslodex 500mg (DRUG), arimidex 1mg (DRUG), faslodex dummy (DRUG), arimidex dummy (DRUG).
Who is sponsoring clinical trial NCT01602380?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.